Video Shorts

Several studies carried out by institutions of repute have shown that Dasatinib 50 mg is as effective as 100 mg with less side effects.

High risk disease is observed in 30% of Myeloma Cases. Identification of high-risk patients is important as proportion of high-risk cases increase with relapses and can lead to significant mortality.

Maintenance therapy with Midostaurin in AML patients with FLT3 mutations has shown potential in improving event-free survival and reducing relapse risk.

Whole Genome Sequencing (Short)
Whole Genome Sequencing is new tool for precision medicine in metastatic castration

There are no randomized clinical trials addressing the continued use of Trastuzumab for Her2 positive MBC patients in prolonged remission and has become important and relevant clinical question.

Majority of Myeloma patients are > 65 years of age at diagnosis & that makes Geriatric Assessment a critical for these patients. Historically we have focused on Cytogenetic & Biochemical evaluation but not so much on geriatric assessment.

Immunotherapy has redefined the treatment of Triple Negative Breast Cancer.

Dr. Joseph Mikhael explains the triad of maintaining the patients on term Lenalidomide maintenance.

Iron chelation therapy (ICT) in MDS is used to manage iron overload from frequent blood transfusions. It involves identifying patients who would benefit most, monitoring iron levels, and managing side effects of chelators

Need to maximise the response to hypomethylating agents: Standard of care for high-risk Myelodysplastic Syndromes is Hypomethylating agents. Average time to response is about 3 months with either Azacytidine or Decitabine.